



**UNITED STATES DEPARTMENT OF COMMERCE**

**Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

#24

MAY 21 1993

Douglas P. Mueller  
Wegner, Cantor, Mueller & Player  
P.O. Box 18218  
Washington, D.C. 20036-8218

Re: Patent Term Extension  
Application for  
U.S. Patent No. 4,455,297

Dear Mr. Mueller:

A certificate under 35 USC § 156 is enclosed extending the term of U.S. Patent No. 4,455,297 for a period of 1,642 days.

*C.E. Van Horn*

Charles E. Van Horn  
Patent Policy & Projects Administrator  
Office of the Assistant Commissioner for Patents

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 11-44  
Rockville, MD 20857

RE: Acel-Imune  
FDA Docket No.: 92E - 0115

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

PATENT NO.: 4,455,297

DATED: June 19, 1984

INVENTORS: Yukio Syukuda et al.

PATENT OWNER: Takeda Chemical Industries, Ltd.

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

1,642 DAYS

with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 20th day of May 1993.



Michael K. Kirk

Acting Commissioner of Patents and Trademarks